Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5144023 | 0.92 | EPHX2 (1.00) | EPHX1EPHX2 | |
| SCHEMBL5146577 | 0.89 | EPHX1 (1.00) | EPHX1EPHX2 | |
| SCHEMBL13651413 | 0.84 | EPHX2 (0.74) | EPHX1EPHX2 | |
| SCHEMBL4345195 | 0.82 | EPHX2 (1.00) | EPHX1EPHX2 | |
| SCHEMBL8233455 | 0.82 | EPHX1 (1.00) | EPHX1EPHX2 | |
| SCHEMBL2731282 | 0.81 | EPHX2 (1.00) | EPHX1EPHX2 | |
| SCHEMBL27778381 | 0.80 | EPHX2 (0.86) | EPHX1EPHX2 | |
| Ar9281 SCHEMBL18464997 | 0.79 | EPHX2 (1.00) | EPHX1EPHX2 | |
| Ar9281 SCHEMBL654229 | 0.79 | EPHX2 (1.00) | EPHX1EPHX2 | |
| SCHEMBL15262678 | 0.79 | EPHX2 (0.86) | EPHX1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-2029539-B1 | N-(piperidinyl)-urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of e.g. hypertension or inflammations | UNIV CALIFORNIA (US) | 2016-06-29 | — | — | EP | disclosed |
| US-9029550-B2 | Conformationally restricted urea inhibitors of soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029550-B2 | Conformationally restricted urea inhibitors of soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029550-B2 | Conformationally restricted urea inhibitors of soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130274476-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | UNIV CALIFORNIA (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130274476-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | UNIV CALIFORNIA (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130274476-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | UNIV CALIFORNIA (US) | 2013-10-17 | — | — | US | disclosed |
| US-8501783-B2 | Conformationally restricted urea inhibitors of soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501783-B2 | Conformationally restricted urea inhibitors of soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130137726-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137726-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137726-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-30 | — | — | US | disclosed |
| US-8188289-B2 | Conformationally restricted urea inhibitors of soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188289-B2 | Conformationally restricted urea inhibitors of soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120035191-A1 | Deuterium-enriched pyrimidine compounds and derivatives | DHANOA DALJIT SINGH (US) | 2012-02-09 | — | — | US | disclosed |
| US-20070225283-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225283-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225283-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225283-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, NCEH1 | EPHX1 1/4885EPHX2 2/4885 |
| US-20120035191-A1 | Deuterium-enriched pyrimidine compounds and derivatives | DBH, OPRK1, PYGB | EPHX1 1914/4885EPHX2 2321/4885 |
| US-20130274476-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, NCEH1 | EPHX1 1/4885EPHX2 2/4885 |
| US-20130137726-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, NCEH1 | EPHX1 1/4885EPHX2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.